GlassScriptPhysician profile
Dedri M Ivory
NPI 1851585004
$12,046.17
in general payments reported to CMS, 2019-2025
26 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $1,027 · 2021: $2,124 · 2022: $1,695 · 2023: $1,994 · 2024: $2,067 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,101.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,677.92 | 2019-2025 | |
| Amgen INC. | $2,022.00 | 2019-2025 | Enbrel, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,249.61 | 2019-2025 | |
| Ucb, INC. | $999.33 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $831.48 | 2019-2025 | Tremfya, Stelara, Remicade |
| Aurinia Pharma U.S., INC. | $581.18 | 2021-2025 | Lupkynis |
| Pfizer INC. | $565.74 | 2019-2024 | |
| Lilly USA, LLC | $468.11 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.99 | 2019-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $352.84 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $325.41 | 2019-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $283.37 | 2019-2025 | Sotyktu, Orencia |
| Horizon Therapeutics Plc | $270.40 | 2020-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $192.53 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $180.28 | 2023-2025 | Idacio, Tyenne |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $152.34 | 2021-2025 | Acthar |
| Sobi, INC | $80.64 | 2022-2025 | |
| Genzyme Corporation | $77.05 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $58.32 | 2024 | |
| Alexion Pharmaceuticals, INC. | $46.45 | 2022-2025 | Strensiq |
| Shorla Oncology INC. | $45.43 | 2024 | |
| Genentech USA, INC. | $35.04 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.99 | 2019 | |
| Organon LLC | $22.25 | 2025 | Hadlima, Renflexis |
| Takeda Pharmaceuticals U.S.A., INC. | $14.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dedri Ivory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.